Vincristine, dactinomycin, cyclophosphamide (VAC) versus VAC/V plus irinotecan (VI) for intermediate-risk rhabdomyosarcoma (IRRMS): A report from the Children’s Oncology Group Soft Tissue Sarcoma Committee.
暂无分享,去创建一个
James R. Anderson | S. Donaldson | D. Rodeberg | S. Spunt | D. Hawkins | W. Meyer | L. Teot | D. Parham | S. Wolden | G. McCowage | A. Hayes-Jordan | K. Brown | L. Mascarenhas | L. Million